Emcure Pharmaceuticals announced a robust financial performance for Q2 FY26, with revenue reaching ₹2,270Cr, a 13.4% year-over-year increase. The company’s EBITDA margins stood at 19.3%, translating to an EBITDA of ₹439Cr, a 15.2% YoY growth. Profit after tax (PAT) soared by 25% to ₹251Cr. The company’s domestic sales grew by 11%, and international sales increased by 16%.
Financial Highlights
Emcure Pharmaceuticals reported strong Q2FY26 results, demonstrating growth across both domestic and international markets. Key figures include:
- Revenue from Operations: ₹2,270Cr (up 13.4% YoY)
- EBITDA: ₹439Cr (up 15.2% YoY), with margins at 19.3%
- Profit After Tax (PAT): ₹251Cr (up 24.7% YoY)
Domestic Performance
Domestic business grew by 10.6%, driven by key therapies and strategic initiatives. Emcure is partnering with Novo Nordisk to launch Poviztra® in India for chronic weight management. Emcure also completed the acquisition of the minority stake in its Zuventus subsidiary this quarter.
International Growth
International business expanded by 15.8%. Europe demonstrated a robust 23% growth, boosted by new product launches and Manx ramp-up. Canada continued its strong growth trajectory with an 18% increase. The Rest of World segment maintained its momentum with non-ARV products.
Segmental Revenue Breakdown
A summary of revenue distribution across geographies:
| Segment | Revenue (₹Cr) | YOY Growth (%) |
| Domestic | 1,031 | 10.6% |
| International | 1,238 | 15.8% |
| EM | 446 | 8.6% |
| EU | 444 | 22.7% |
| CA | 348 | 17.5% |
